• South African regulators registered a PD-1 inhibitor from Dr. Reddy’s Laboratories for recurrent or metastatic nasopharyngeal carcinoma.
• The authorization expands local access to immunotherapy for a rare head and neck cancer with limited treatment options.
• GLOBOCAN 2024 put five-year prevalence in South Africa at 0.66 cases per 100,000 people.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.